You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
Proceeds from the placement will be used for general corporate and working capital purposes, including commercialization of the firm's ICE COLD-PCR technology.
The partners will augment the multiplexing capabilities of ICE COLD-PCR, which was developed at Dana-Farber and is exclusively licensed to Transgenomic.
Roche has received regulatory clearance to finalize its acquisition of Kapa Biosystems, the company announced this week.
Transgenomic has completed its divestment of its Genetic Assays and Platforms unit to Adstec
The lower sales from contract laboratory services reflect Transgenomic's continued refocusing on its core ICE-COLD PCR molecular diagnostic technology.
Adstec will assume the business, financial, and human resource commitments of the business and pay Transgenomic $300,000 for stock and inventory related to the business.
The deal covers four of Transgenomic's liquid biopsy cancer assays, which detect actionable mutations associated with sensitivity or resistance to therapy.
The company sold the technology and assets to Edge BioSystems as part of an ongoing effort to divest legacy non-core businesses and product lines.
The firm has signed Spectron Scientific and Sowa Trading Company to distribute its ICEme mutation enrichment kit in China and Japan, respectively.
Adjusting for the company's third quarter 2014 sale of its Surveyor kits product line, Q2 revenue increased about 11 percent year over year.
Nature News writes that additional details about the UK plan for an agency to support high-risk, high-reward science are needed.
The New York Times reports that the US Food and Drug Administration has authorized Johnson & Johnson's SARS-CoV-2 vaccine.
The Wall Street Journal writes new studies are giving glimpses into the origins of SARS-CoV-2.
In PLOS this week: analysis of Plasmodium population structure, qPCR assay to diagnose scabies, and more.